Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
The programmed-death-1 inhibitors selectively block programmed-death-1 interaction with its receptor, which restores active T-cell response directed at tumor cells, inducing an anti-tumor effect. This nonspecific activation of the immune system can also lead to a wide spectrum of side effects. Nivolumab has been used effectively to prolong survival in patients with metastatic melanoma and is recommended as a category 1 agent for systemic therapy in metastatic or unresectable melanoma per the National Comprehensive Cancer Network guidelines. We present a case of a 64-year-old woman who began nivolumab therapy for metastatic melanoma. After six doses of nivolumab therapy, the patient experienced generalized hypopigmentation on her face, chest, back, arms, and lower extremities. Although vitiligo has been reported in as many as 10.7% of patients undergoing nivolumab therapy in some clinical trials, we believe this is the first case to describe the progression of nivolumab-induced vitiligo in a metastatic melanoma patient. This case provides significant insight into the onset, symptoms, development, and treatment options for patients experiencing vitiligo as a result of nivolumab therapy.
Seton Healthcare Family, Austin, TX, USA.
Lindsay A
LA
Edmondson
Seton Healthcare Family, Austin, TX, USA.
Leticia V
LV
Smith
Seton Healthcare Family, Austin, TX, USA.
Alka
A
Mallik
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D000077594:Nivolumab; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014820:Vitiligo / Q000139:chemically induced* / Q000175:diagnosis*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab
Immunotherapy; nivolumab; programmed-death-1 inhibitors; vitiligo